特朗普拟2028年起对进口仿制药加征100%至200%关税，Sandoz股价承压

Oil hovers near six-week high as expanding Mideast conflict fuels supply fears
Investing.com -- Sandoz Group AG (SIX:SDZ) shares fell nearly 3% on Wednesday after U.S. President Donald Trump unveiled plans to impose steep tariffs on imported generic medicines from 2028, raising concerns over the long-term outlook for one of the world's largest generic drugmakers.
The stock dropped 2.9% to CHF 64.58, making it one of the weakest performers on the SMI, which was up 0.3%.
Save 60% on InvestingPro for Fair Value, analyst targets and more
Trump said imported generic drugs will remain exempt from tariffs for two years beginning August 1, before facing a 100% tariff from August 2028 and a 200% levy a year later if production is not shifted to the United States. The proposal is aimed at encouraging pharmaceutical companies to localize manufacturing.
As one of the world's largest producers of generic medicines and biosimilars, Sandoz is seen as particularly exposed to the proposal given its significant international manufacturing footprint and sizeable U.S. business.
The company has previously said it would engage with U.S. policymakers and that it was too early to assess the potential impact of the proposal on its manufacturing footprint or investment plans.
While the tariffs would not take effect for another two years, investors are increasingly focused on how multinational generic drugmakers may need to accelerate U.S. manufacturing investments or restructure supply chains to preserve margins if the measures are implemented.
Industry groups have also warned that relocating low-cost generic drug production to the U.S. could significantly increase manufacturing costs, potentially affecting medicine affordability.